Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0005659700
Thu, 14.11.2024
Eckert & Ziegler SE
Berlin, November 14, 2024. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased its sales by 17% year-on-year to € 215.5 million in the first nine months of 2024. Recurring EBIT from continuing operations (adjusted EBIT) rose by 24% to € 46.7 million. Net income (from continuing and discontinued operations) grew by 15% and reached € 23.4 m [ … ]
Tue, 08.10.2024
Eckert & Ziegler SE
Berlin, Germany and Sydney, Australia - 08. October 2024 - Eckert & Ziegler (ISIN DE0005659700, SDAX) and GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company specialising in developing antibody radiopharmaceuticals for solid tumors, today announced a new global clinical supply agreement. Eckert & Ziegler will provide its [ … ]
Wed, 02.10.2024
Eckert & Ziegler SE
Berlin, 2 October 2024. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) announces that the spin-off resolution approved at the Annual General Meeting on 26 June 2024 was entered in the commercial register of the Charlottenburg (Berlin) District Court today. With the entry in the commercial register of Eckert & Ziegler SE, the spin-off of Pe [ … ]
Tue, 20.08.2024
Eckert & Ziegler SE
Berlin, 20.08.2024. In the presence of the Saxon State Ministers Martin Dulig and Thomas Schmidt as well as the Mayor of Dresden Dirk Hilbert, the medical technology company Eckert & Ziegler today inaugurated its new 1,700 square meter facilities in Dresden with around 200 guests. The Dresden-Rossendorf site produces and delivers high-tech syst [ … ]
Tue, 13.08.2024
Eckert & Ziegler SE
Berlin, August 13, 2024 - Eckert & Ziegler and Telix Pharmaceuticals Limited (Telix) today announced the signing of a significant multi-year agreement under which Eckert & Ziegler will serve as the European contract manufacturing organization (CMO) for Telix's ProstACT GLOBAL Phase III study. The contract covers the supply of the entire Eur [ … ]
Fri, 09.08.2024
Eckert & Ziegler SE
2nd Quarter 2024:
Sales: € 77.8 Mio. million (PY: € 60.1 million)
EBIT before special items: € 17.5 million (PY: € 12.0 million)
Net income: € 9.5 million (PY: € 6.2 million)
1st Half Year 2024:
Sales: € 145,4 million (PY: € 118.0 million)
EBIT before special items: € 32.5 million (PY: € 22.6 million)
Net income: € 18.0 million (PY: € 10.9 mi [ … ]
Mon, 05.08.2024
Eckert & Ziegler SE
August 5, 2024 - Berlin - Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) has received approval from the European Commission (EC) for its Ge-68/Ga-68 radionuclide generator GalliaPharm®. The generator was first launched in 2014 and is today approved in 17 European countries and many other key international markets. With the EC approval [ … ]
Wed, 26.06.2024
Eckert & Ziegler SE
Berlin, June 26, 2024. The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) today resolved to split-off Pentixapharm AG from Eckert & Ziegler SE and to distribute a dividend of EUR 0.05 per share for the 2023 financial year.
As in the previous year, the Annual General Meeting was held as an in-person event at Eckert & [ … ]
Tue, 25.06.2024
Eckert & Ziegler SE
Würzburg/Berlin, Germany, 25 June 2024. Pentixapharm AG, a radiopharmaceutical development company wholly owned by Eckert & Ziegler SE, today announced that it has received encouraging feedback from the U.S. Food and Drug Administration (FDA) following a recent Type C meeting with the Agency to directly proceed into a pivotal phase III registra [ … ]
Tue, 25.06.2024
Eckert & Ziegler SE
Würzburg/Berlin, Germany, 25 June 2024. Pentixapharm AG, a radiopharmaceutical development company wholly owned by Eckert & Ziegler SE, today announced that it has received encouraging feedback from the U.S. Food and Drug Administration (FDA) following a recent Type C meeting with the Agency to directly proceed into a pivotal phase III registra [ … ]